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In silicoAbstract In this paper we report the design and synthesis of novel derivatives of the 4H-3,1-
benzothiazinone type and heterocyclic analogues, i.e. benzofuro-, azolo- and thieno-1,3-thiazin-4-
ones possessing 2,4-dihydroxyphenyl substituent. The compounds were obtained by the one-step
reaction of aminobenzamides or heterocyclic aminocarboxamides with aryl-modiﬁed sulﬁnyl
bis[(2,4-dihydroxyphenyl)methanethione]. Evaluation of their antiproliferative potency against
human cancer cell lines showed that the activity of some analogues was similar to that of cisplatin.
The highest activity and low toxicity were found for 6-tert-butyl-2-(5-chloro-2,4-dihydroxyphenyl)-
4H-thieno[3,2-d ][1,3]thiazin-4-one. The structure–activity elucidation reveals that the most active
compounds are those with a thienothiazin-4-one and benzofuro[3,2-d][1,3]thiazin-4-one skeleton
and the presence of the hydrophobic substituent (Et, Cl) in the benzenediol moiety increases their-, azolo-
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and thieno-1,3-thiazinone resorcinol hybridsantiproliferative potency. The ADMET properties of selected compounds including metabolic sta-
bility and toxicity proﬁle were estimated in silico.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heterocyclic resorcinols are special group of compounds use-
ful for the anticancer drug design and development. They exhi-
bit a broad spectrum of antitumour activity and a low risk of
drug resistance induction is assumed (Pratt and Toft 2003;
Uehara 2003). They act as heat-shock protein 90 (Hsp90) inhi-
bitors (Blagg and Kerr 2006; Jhaveri et al., 2012). The most
important in this area are pyrazole (I) (Fig. 1) (McDonald
et al., 2006; Smith et al., 2006) and isoxazole scaffold based
resorcinols (Davenport et al., 2010; Hartmann et al., 2013).
Luminespib (NVP-AUY922) (II) (Fig. 1). Isoxazole resorcinol
derivative was entered in the phase I/II clinical trials for the
patients with advanced solid tumours and multiple myeloma
(Davenport et al., 2010). Recently 1,3,5-trisubstituted 1,2,3-
triazole scaffold based compounds with resorcinol moiety were
described as the small-molecule Hsp90 inhibitors of potent
anticancer activity (Taddei et al., 2014). The most promising
ganetespib (III) (Fig. 1) is developed for treating haematolog-
ical cancers and multiple solid tumours (Zagouri et al., 2013).
Two ring fused heterocycles benzisoxazoles (IV) (Gopalsamy
et al., 2008) and 2,3-dihydrobenzoimidazol-2-ones (V)
(Fig. 1) with 2,4-dihydroxyphenyl substituent are also known
as compounds of potent anticancer potency (Jensen et al.,
2008). X-ray crystallographic studies and SAR elucidation
showed that the presence of hydrophobic substituents in posi-
tion 5 of resorcinol moiety improves their anticancer potency
by creating additional hydrophobic interactions in the binding
site (Yang et al., 2011).
The research carried out by our team demonstrated
antiproliferative activity of other heterocyclic resorcinols. It
includes derivatives with one ring system of 1,3,4-thiadiazole
(Matysiak et al., 2006) and two fused rings of 4H-3,O
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. Arabian Journal of Chemistry (2015),1-benzothiazine (VI) (Fig. 1) (Niewiadomy et al., 2011), 1,3-
thiazolo[5,4-b]pyridine and 1H-benzimidazole (Karpin´ska
et al., 2011). The compounds showed high activity against
the human derived cancer cells. An antiproliferative potency
of some derivatives was similar to that of cisplatin. The SAR
studies exhibited that the presence of a chlorine atom or Et
substituents in position 5 of the resorcinol ring has a beneﬁcial
effect on the activity. Based on the promising data of
preliminary studies of 2-(2,4-dihydroxyphenyl)-4H-3,1-
benzothiazin-4-one we decided to focus on other skeletons
fused heterocycles to thiazinone as potential anticancer agents
(Matysiak 2006).
Benzo/heterocyclo-1,3-thiazin-4-ones have been relatively
weakly studied in the area of synthesis and medicinal
chemistry. Besson and co-workers transformed anthranilic
acid to 4-oxo-4H-3,1-benzothiazine-2-carbonitrile using
4,5-dichloro-1,2,3-dithiazolium chloride or PPh3 in CH2Cl2
(Besson et al., 1995a; Besson et al., 1995b; Besson et al.,
1996). 2-Substituted derivatives were obtained from methyl
2-(3-alky/arylthioureido)benzoates, or 2-thioureidobenz-
amides, or 2-thioureidobenzonitriles using concentrated
H2SO4 or HCl as cyclizing reagent (Gu¨tschow et al., 1991;
Neuman and Gu¨tschow 1995). The synthesis of thieno-1,3-
thiazin-4-ones was described from 2-thioureidothiophene-3-c
arbonitriles and the corresponding acid anhydride in the
medium of concentrated sulphuric acid (Gu¨tschow et al.,
1992). In other reactions methyl 2-(3-aroylthioureido)-3-thio
phenecarboxylates and ethyl 2-(3-benzylthioureido)-3-thiophe
necarboxylates were applied as initial reagents (Gu¨etschow
et al., 2012; Leistner et al., 1988; Leistner et al., 1987). A
two-step synthesis of the thieno[2,3-d][1,3]thiazin-4-one skele-
ton with 2-acyl substituent was also presented (Gu¨tschow
and Leistner 1995). Pyrazolo[3,4-d][1,3]thiazin-4-ones andO
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Design, synthesis and antiproliferative activity against human cancer cell lines 3pyrazolo[1,5-c][1,3,5]thiadiazine-4-one were obtained in the
reaction of trichloromethylchloroformate with N-(1-alkyl/
aryl-5-pyrazolyl)thiocarboxamides or N-(3-methyl-5-pyrazolyl)
thiobenzamide respectively (Vicentini et al., 1994). The
Lawesson reagent and 5(4)-substituted amino-4(5)-
ethoxycarbonyl-1(3H)-imidazoles were used for the synthesis
of imidazo[4,5-d][1,3]thiazine-7(3H)-thiones (Hara et al.,
1992; Kaneko et al., 1991). 4,5-Diaryl-2,3-dihydro-2-mercaptoi
midazoles in the reaction with bromopropionic acid create 6,7-
diaryl imidazo[2,1-b]-1,3-thiazin-4-ones of considerable
antimicrobial activity (Salama and Almotabacani 2004). The
developed method allowed to obtain only a few analogues with
limited reactivity of substrates.
In this paper we present the design, synthesis and biological
evaluation of a series of novel 4H-3,1-benzothiazin-4-ones and
of heterocyclic analogues: benzofuro-, azolo- and
thienothiazin-4-ones. The activity of the compounds was addi-
tionally differentiated by the presence of a modiﬁed 2,4-
dihydroxyphenyl moiety. Because physico-chemical properties
and toxicity of compounds are a major reason for drug candi-
date failure in trials, therefore in silico ADMET properties of
the obtained compounds were evaluated.
2. Experimental
2.1. Analytical studies
Melting points (mp) were determined using a BU¨CHI B-540
(Flawil, Switzerland) melting point apparatus. The elemental
analysis (C, H, N) was performed on Perkin-Elmer 2400.
The IR spectra were measured with a Perkin–Elmer FT-IRNH2
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Scheme 1 Synthesis scheme of 4H-3,1-benzothiazin-4-ones (a) and 4
were used.
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IR spectrometer (ATR) in the range of 600–4000 cm1.
NMR spectra were recorded in DMSO-d6 using a Bruker
DRX 500 instrument. Chemical shifts (d, ppm) were described
in relation to tetramethylsilane (TMS). The MS spectra (EI,
70 eV) were recorded using the apparatus AMD-604.
2.2. Synthesis of compounds
2.2.1. A general procedure for the synthesis of compounds 1a–9a
A mixture of the corresponding 2-amino-N-phenylbenzamide
(2a, 3a–9a) or 2-amino-N-methylbenzohydrazide (1a, 3a, 4a)
(1.5 mmol) and electrophile STB (1.5 mmol) in MeOH
(8 mL) was treated to reﬂux for 3–3.5 h (Scheme 1). The hot
mixture was ﬁltered via a Bu¨chner funnel. The ﬁltrate was con-
centrated and the formed solid was ﬁltered off (compounds 1a,
2a, 3a, 7a, 8a, 9a) or the solid formed during the synthesis was
combined with that obtained after the ﬁltrate concentration
(4a). In the case of compounds 5a and 6a the reaction mixture
was left at room temperature (24 h) and ﬁltered. The com-
pounds were crystallized from MeOH (5 mL) (compounds
1a, 2a, 4a–9a) or from MeOH/H2O (1:1, 5 mL) (3a).
2.2.1.1. 2-(2,4-Dihydroxy-3-methylphenyl)-4H-3,1-benzoth-
iazin-4-one (1a). Yield: 82%, mp: 224–227 C. 1H NMR
(500 MHz, DMSO-d6) d: 13.85 (s, 1H, C(20)-OH), 10.47 (s,
1H, C(40)-OH), 8.11 (dd, J= 7.95 and 1.55 Hz, 1H, C(5)-H),
7.94 (td, J= 8.47 and 1.58 Hz, 1H, C(7)-H), 7.85 (dd,
J= 8.11 and 1.00 Hz, 1H, C(8)-H), 7.61 (td, J= 6.85 and
1.17 Hz, 1H, C(6)-H), 7.45 (d, J= 8.87 Hz, 1H, C(60)-H),
6.54 (d, J= 8.9 Hz, 1H, C(50)-H), 2.04 (s, 3H, Me) ppm; 13CS OH
OH
S OH
OH
1a: R1= Me, R2 = H
3a: R1 = H, R2 = Et
4a: R1 = H, R2 = Cl
2a: R2 = Me, X=Y = R1 = H
5a:Y=F, R1 = R2 = X = H
6a: X = F, R1 = R2 = Y = H
7a: Y=Cl, R1 = Me, R2 = X = H
8a: Y=Cl, R2 = Et, R1 =X = H
9a: Y=Cl, R2 = Cl, R1 = X = H
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R2
R2
R1
S OH
OH
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1b: R2 = H
2b: R2= Et
: R1 = R2 = H
: R1 = Me, R2 = H
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4 J. Matysiak et al.NMR (125 MHz, DMSO-d6) d: 182.4, 164.7, 161.6, 160.0,
146.7, 137.2, 129.6, 129.1, 126.5, 124.9, 119.8, 111.6, 110.6,
108.4, 8.5 ppm; IR (KBr): 3567 (OH), 3468 (OH), 3067
(CH), 2922 (CH), 1660 (C‚O), 1610 (C‚N), 1539 (C‚C),
1501 (C‚C), 1470, 1369, 1311, 1286, 1250 (CAOH), 1154,
1111, 1075, 1058, 963, 923, 880, 791, 774, 707 cm1; EI-MS
m/z (%): 285 (M+, 100), 225 (44), 202 (7), 196 (9), 170 (3),
167 (2), 122 (8), 102 (2), 94 (6), 77 (6), 65 (4), 50 (3), 39 (4).
Anal. Calcd for C15H11NO3S (285.05): C, 63.14; H, 3.89; N,
4.91; Found: C, 63.10; H, 3.88; N, 4.95.
2.2.1.2. 2-(2,4-Dihydroxy-5-methylphenyl)-4H-3,1-benzoth-
iazin-4-one (2a). Yield: 83%, mp: 225–228 C. 1H NMR
(500 MHz, DMSO-d6) d: 13.85 (s, 1H, C(20)-OH), 10.49 (s,
1H, C(40)-OH), 8.12 (dd, J= 7.93 and 1.37 Hz, 1H, C(5)-H),
7.94 (td, J= 6.99 and 1.55 Hz, 1H, C(7)-H), 7.85 (d,
J= 8.07 Hz, 1H, C(8)-H), 7.61 (td, J= 7.83 and 1.05 Hz,
1H, C(6)-H), 7.46 (s, 1H, C(60)-H), 6.56 (s, 1H, C(30)-H),
2.04 (s, 3H, Me) ppm; 13C NMR (125 MHz, DMSO-d6) d:
181.8, 164.1, 161.1, 159.5, 146.2, 136.5, 129.0, 128.4, 125.8,
124.3, 119.2, 111.0, 110.1, 107.9, 8.0 ppm; IR (KBr): 3477
(OH), 3082 (OH), 2922 (CH), 2854 (CH), 1661 (C‚O), 1611
(C‚N), 1540 (C‚C), 1501 (C‚C), 1471, 1449, 1374, 1309,
1284, 1250 (CAOH), 965, 923, 789, 775, 706 cm1; MS (EI)
m/z (%): 285 (M+, 100), 271 (2), 239 (2), 225 (51), 202 (10),
196 (14), 168 (54), 151 (2), 148 (2), 122 (4), 94 (8), 65 (3), 39
(2). Anal. calc. for C15H11NO3S (285.05): C, 63.14; H, 3.89;
N, 4.91; Found: C, 63.23; H, 3.88; N, 4.86.
2.2.1.3. 2-(5-Ethyl-2,4-dihydroxyphenyl)-4H-3,1-benzothiazin-
4-one (3a). Yield: 83%, mp: 245–247 C. 1H NMR
(500 MHz, DMSO-d6) d: 10.50 (s, 1H, C(20)-OH), 10.12 (s,
1H, C(40)-OH), 7.85 (dd, J= 7.87 and 1.5 Hz, 1H, C(5)-H),
7.57 (m, 1H, C(7)-H), 7.43 (s, 1H, C(60)-H), 7.31 (d,
J= 7.82 Hz, 1H, C(8)-H), 7.22 (t, J= 7.57 Hz, 1H, C(6)-H),
6.61 (s, 1H, C(30)-H), 2.50 (q, J= 7.5 Hz, 2H, CH2Me), 1.16
(t, J= 7.5 Hz, 3H, CH2Me) ppm;
13C NMR (125 MHz,
DMSO-d6) d: 182.0, 163.5, 161.3, 159.5, 146.5, 136.5, 129.2,
128.3, 127.4, 124.2, 123.3, 119.1, 110.3, 112.8, 22.0,
14.0 ppm; IR (KBr): 3421 (OH), 3078 (OH), 2963 (CH),
2934 (CH), 2871 (CH), 1655 (C‚O), 1618 (C‚N), 1553
(C‚C), 1488, 1469, 1446, 1433, 1407, 1343, 1296, 1264, 1245
(CAOH), 1204, 1186, 1161, 1123, 1101, 1061, 1041, 1026,
965, 942, 917, 893, 867, 842, 788, 760, 718 cm1; EI-MS m/z
(%): 299 (M+, 5), 283 (M+-Me, 8), 268 (100), 253 (3), 239
(7), 224 (18), 211 (4), 198 (11), 183 (4), 168 (3), 148 (7), 120
(7), 104 (2), 92 (5), 77 (7), 65 (5), 51 (4), 39 (3). Anal. Calcd
for C16H13NO3S (299.34): C, 64.20; H, 4.38; N, 4.68; Found:
C, 64.28; H, 4.36; N, 4.62.
2.2.1.4. 2-(5-Chloro-2,4-dihydroxyphenyl)-4H-3,1-benzoth-
iazin-4-one (4a). Yield: 83 %, mp: 272–274 C. 1H NMR
(500 MHz, DMSO-d6) d: 12.81 (s, 1H, C(20)-OH), 11.50 (s,
1H, C(40)-OH), 8.15 (dd, 1H, J= 6.55 and 1.3 Hz, C(5)-H),
7.96 (m, 1H, C(7)-H), 7.92 (d, J= 7.15 Hz, 1H, C(8)-H),
7.77 (s, 1H, C(60)-H), 7.67 (m, 1H, C(6)-H), 6.73 (s, 1H,
C(30)-H) ppm; IR (KBr): 3349 (OH), 2946 (CH), 2834 (CH),
1658 (C‚C), 1641 (C‚N), 1598 (C‚C), 1531 (C‚C), 1461,
1448, 1413, 1255 (CAOH), 1197, 1113, 1023, 778 cm1; EI-
MS m/z (%): 305 (M+, 100), 278 (5), 247 (42), 214 (9), 187
(15), 153 (11), 109 (6), 77 (4), 65 (8), 39 (6), 33 (14). Anal.Please cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolife
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),Calcd for C14H8ClNO3S (305.74): C, 55.00; H, 2.64; N, 4.58;
Found: C, 54.91; H, 2.66; N, 4.62.
2.2.1.5. 2-(2,4-Dihydroxyphenyl)-6-ﬂuoro-4H-3,1-benzothiazin-
4-one (5a). Yield: 71%, mp: 288–289 C. 1H NMR (500 MHz,
DMSO-d6) d: 12.92 (s, 1H, C(20)-OH), 10.56 (s, 1H, C(40)-OH),
8.00 (m, 1H, C(5)-H), 7.87 (m, 2H, C(7,8)-H), 7.66 (d,
J= 8.85 and 2.34 Hz, 1H, C(60)-H), 6.45 (dd, J= 8.85 and
2.34 Hz, 1H, C(50)-H), 6.38 (d, J= 2.32 Hz, 1H, C(30)-H)
ppm; IR (KBr): 3406 (OH), 2946 (CH), 1667 (C‚O), 1628
(C‚N), 1552 (C‚C), 1514 (C‚C), 1483, 1447, 1362, 1329,
1275, 1238 (CAOH), 1219, 1187, 1140, 1106, 988, 944, 856,
738 cm1; EI-MS m/z (%): 289 (M+, 100), 229 (49), 201
(13), 172 (10), 108 (19), 94 (4), 69 (4). Anal. Calcd for
C14H8FNO3S (289.28): C, 58.13; H, 2.79; N, 4.84; Found: C,
58.23; H, 2.75; N, 4.92.
2.2.1.6. 2-(2,4-Dihydroxyphenyl)-5-ﬂuoro-4H-3,1-benzothiazin-
4-one (6a). Yield: 71%, mp: 285–286 C. 1H NMR (500 MHz,
DMSO-d6) d: 13.07 (s, 1H, C(20)-OH), 10.62 (s, 1H, C(40)-OH),
7.93 (m, 1H, C(7)-H), 7.71 (m, 1H, C(8)-H), 7.69 (d,
J= 8.12 Hz, 1H, C(6)-H), 7.64 (d, J= 8.86 Hz, 1H, C(60)-
H), 6.48 (dd, J= 8.87 and 2.37 Hz, 1H, C(50)-H), 6.38 (d,
J= 2.38 Hz, 1H, C(30)-H) ppm; IR (KBr): 3412 (OH), 2928
(CH), 1674 (C‚O), 1633 (C‚N), 1548 (C‚C), 1526
(C‚C), 1509 (C‚C), 1492, 1450, 1369, 1341, 1282, 1267,
1244 (CAOH), 1208, 1176, 1137, 1125, 993, 950, 863, 742,
709 cm1; EI-MS m/z (%): 289 (M+, 100), 261 (5), 229 (33),
204 (7), 201 (17), 172 (15), 108 (30), 94 (6), 80 (5), 69 (7), 52
(4), 39 (4). Anal. Calcd for C14H8FNO3S (289.28): C, 58.13;
H, 2.79; N, 4.84; Found: C, 58.08; H, 3.00; N, 4.79.
2.2.1.7. 6-Chloro-2-(2,4-dihydroxy-3-methylphenyl)-4H-3,1-
benzothiazin-4-one (7a). Yield: 88%, mp: 233–234 C. 1H
NMR (500 MHz, DMSO-d6) d: 13.61 (s, 1H, C(20)-OH),
10.53 (s, 1H, C(40)-OH), 8.05 (d, J= 2.41 Hz, 1H, C(5)-H),
8.00 – 7.93 (m, 2H, C(7,8)-H), 7.48 (d, J= 8.9 Hz, 1H,
C(60)-H), 6.51 (d, J= 8.48 Hz, 1H, C(50)-H), 2.04 (s, 3H,
Me) ppm; 13C NMR (125 MHz, DMSO-d6) d: 181.0, 165.1,
160.4, 159.9, 146.9, 135.0, 130.4, 127.6, 126.0, 123.3, 122.4,
114.6, 110.3, 106.7, 8.13 ppm; IR (KBr): 3386 (OH), 2955
(CH), 2861 (CH), 1653 (C‚O), 1618 (C‚N), 1556 (C‚C),
1519 (C‚C), 1462, 1408, 1361, 1324, 1278, 1236 (CAOH),
1221, 1207, 1190, 1137, 1062, 1045, 978, 890, 875, 840, 821,
794, 776, 751, 728 cm1; EI-MS m/z (%): 319 (M+, 100),
261 (21), 259 (53), 236 (6), 230 (10), 122 (6), 94 (12), 75 (3).
Anal. Calcd for C15H10ClNO3S (319.76): C, 56.34; H, 3.15;
N, 4.38; Found: C, 56.43; H, 3.15; N, 4.46.
2.2.1.8. 6-Chloro-2-(5-ethyl-2,4-dihydroxyphenyl)-4H-3,1-ben-
zothiazin-4-one (8a). Yield: 88%, mp: 254–255 C. 1H NMR
(500 MHz, DMSO-d6) d: 12.79 (s, 1H, C(20)-OH), 10.57 (s,
1H, C(40)-OH), 8.05 (d, J= 2.50 Hz, 1H, C(5)-H), 7.96 (dd,
J= 8.70 and 2.52 Hz, 1H, C(7)-H), 7.89 (d, J= 8.74 Hz,
1H, C(8)-H), 7.46 (s, 1H, C(60)-H), 6.43 (s, 1H, C(30)-H),
2.49 (q, J= 7.45 Hz, 2H, CH2Me), 1.13 (t, J= 7.47 Hz, 3H,
CH2Me) ppm;
13C NMR (125 MHz, DMSO-d6) d: 182.1,
164.3, 162.0, 159.8, 146.0, 136.7, 132.9, 132.1, 128.3, 124.1,
123.8, 120.6, 111.1, 103.3, 22.5, 14.6 ppm; IR (KBr): 3397
(OH), 2967 (CH), 2934 (CH), 2875 (CH), 1642 (C‚O), 1624
(C‚N), 1558 (C‚C), 1526 (C‚C), 1467, 1402, 1345, 1318,rative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
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Design, synthesis and antiproliferative activity against human cancer cell lines 51283, 1248 (CAOH), 1220, 1205, 1183, 1138, 1059, 977, 939,
888, 876, 831, 813, 798, 770, 742, 721 cm1; EI-MS m/z (%):
333 (M+, 100), 300 (M+-Me, 74), 273 (5), 258 (33), 167 (3),
148 (7), 69 (4). Anal. Calcd for C16H12ClNO3S (333.68): C,
57.57; H, 3.62; N, 4.20; Found: C, 57.66; H, 3.58; N, 4.26.
2.2.1.9. 6-Chloro-2-(5-chloro-2,4-dihydroxyphenyl)-4H-3,1-
benzothiazin-4-one (9a). Yield: 86%, mp: 307–309 C. 1H
NMR (500 MHz, DMSO-d6) d: 12.46 (s, 1H, C(20)-OH),
11.36 (s, 1H, C(40)-OH), 8.07 (d, J= 2.31 Hz, 1H, C(5)-H),
8.02 (m, 2H, C(7,8)-H), 7.81 (s, 1H, C(60)-H), 6.63 (s, 1H,
C(30)-H) ppm; IR (KBr): 3453 (OH), 3099 (OH), 2921 (CH),
2852 (CH), 1679 (C‚O), 1608 (C‚N), 1530 (C‚C), 1475,
1413, 1259, 1194, 1026, 835, 740 cm1; EI-MS m/z (%): 339
(M+, 100), 305 (5), 283 (10), 279 (64), 251 (11), 216 (9), 188
(10), 169 (7), 142 (23), 114 (5), 75 (10), 40 (6). Anal. Calcd
for C14H7Cl2NO3S (340.18): C, 49.43; H, 2.06; N, 4.12;
Found: C, 49.51; H, 2.05; N, 4.18.
2.2.2. A general procedure for the synthesis of compounds 1b, 2b
A mixture of 2-amino-N-phenylbenzothioamide (1.5 mmol)
and the corresponding electrophile STB (1.5 mmol) in
MeOH (8 mL) was treated to reﬂux for 3.5 h (Scheme 1).
The hot mixture was ﬁltered via a Bu¨chner funnel and the ﬁl-
trate was concentrated. The compounds were crystallized from
MeOH (5 mL).
2.2.2.1. 2-(2,4-Dihydroxyphenyl)-4H-3,1-benzothiazine-4-
thione (1b). Yield: 71%, mp: 195–196 C. 1H NMR
(500 MHz, DMSO-d6) d: 12.76 (s, 1H, C(20)-OH), 10.54 (s,
1H, C(40)-OH), 8.61 (dd, J= 8.2 and 1.2 Hz, 1H, C(8)-H),
7.97 (td, J= 8.21 and 1.4 Hz, 1H, C(7)-H), 7.82 (d,
J= 8.09 Hz, 1H, C(5)-H), 7.75 (d, J= 8.86 Hz, 1H, C(60)-
H), 7.62 (td, J= 7.09 and 1.16 Hz, 1H, C(6)-H), 6.47 (dd,
J= 8.88 and 2.37 Hz, 1H, C(50)-H), 6.39 (d, J= 2.4 Hz, 1H,
C(30)-H) ppm; 13C NMR (125 MHz, DMSO-d6) d: 210.2,
164.3, 163.8, 161.5, 140.6, 137.6, 130.5, 129.9, 129.6, 126.8,
126.0, 110.6, 109.4, 103.7 ppm; IR (KBr): 3413 (OH), 1625
(C‚N), 1595 (C‚N), 1561 (C‚C), 1502 (C‚C), 1459,
1439, 1345, 1325, 1242 (CAOH), 1196, 1160, 1124, 1017
(C‚S), 982, 937, 828, 762 cm1; EI-MS m/z (%): 287 (M+,
100), 254 (11), 243 (3), 223 (6), 218 (24), 211 (18), 186 (7),
183 (14), 154 (14), 152 (9), 120 (6), 108 (29), 77 (11), 69 (10),
50 (7), 45 (5), 39 (6). Anal. Calcd for C14H9NO2S2 (287.36):
C, 58.52; H, 3.16; N, 4.87; Found: C, 58.62; H, 3.15; N, 4.91.
2.2.2.2. 2-(5-Ethyl-2,4-dihydroxyphenyl)-4H-3,1-benzothiazine-
4-thione (2b). Yield: 71%, mp: 220–221 C. 1H NMR
(500 MHz, DMSO-d6) d: 10.58 (s, 1H, C(20)-OH), 10.04 (s,
1H, C(40)-OH), 8.61 (dd, J= 8.2 and 1.38 Hz, 1H, C(8)-H),
7.98 (m, 1H, C(7)-H), 7.82 (d, J= 7.7 Hz, 1H, C(5)-H), 7.61
(m, 1H, C(6)-H), 7.58 (s, 1H, C(60)-H), 6.46 (s, 1H, C(30)-H),
2.35 (m, 2H, CH2Me), 1.14 (t, J= 7.47 Hz, 3H, CH2Me)
ppm; 13C NMR (125 MHz, DMSO-d6) d: 210.0, 163.79,
161.43, 159.21, 140.32, 137.10, 129.94, 128.97, 127.51, 126.28,
123.55, 109.60, 102.91, 22.04, 14.31, 14.12 ppm; IR (KBr):
3201, 3173, 2963, 1616 (C‚N), 1571 (C‚C), 1521 (C‚C),
1459, 1418, 1381, 1322, 1244 (CAOH), 1208, 1140, 1015
(C‚S), 937, 874, 762 cm1; EI-MS m/z (%): 315 (M+, 77),
300 ([M-Me]+, 97), 296 (45), 281 (100), 267 (5), 251 (15), 239
(6), 224 (41), 180 (5), 162 (10), 148 (14), 119 (7), 108 (7), 91Please cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolifer
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),(5), 77 (15), 69 (14), 65 (9), 40 (30), 36 (8). Anal. Calcd for
C16H13NO2S2 (315.41): C, 60.93; H, 4.15; N, 4.44; Found: C,
61.02; H, 4.14; N, 4.47.
2.2.3. A general procedure for the synthesis of compounds 1c–4c
A mixture of the corresponding aminothiophenecarboxamide
(1.8 mmol) and electrophile STB (1.8 mmol) in MeOH
(8 mL) (Scheme 2) was treated to reﬂux for 2.5–3 h. The hot
mixture was ﬁltered via a Bu¨chner funnel. The compounds
were crystallized from MeOH (5 mL).
2.2.3.1. 2-(5-Chloro-2,4-dihydroxyphenyl)-4H-thieno[3,2-
d][1,3]thiazin-4-one (1c). Yield: 81%, mp: 293–294 C. 1H
NMR (500 MHz, DMSO-d6) d: 12.11 (s, 1H, C(20)-OH),
11.25 (s, 1H, C(40)-OH), 8.43 (d, J= 5.21 Hz, 1H, C(6)-H),
7.84 (s, 1H, C(60)-H), 7.73 (d, J= 5.24 Hz, 1H, C(7)-H),
6.62 (s, 1H, C(30)-H) ppm; IR (KBr): 3332 (OH), 3089 (OH),
2889 (CH), 1659 (C‚O), 1620 (C‚N), 1511 (C‚C), 1490,
1429, 1392, 1351, 1243, 1221 (CAOH), 1196, 1090, 1039,
1026, 959, 832, 767, 747, 705 cm1; EI-MS m/z (%): 311
(M+, 100), 85 (5), 283 (12), 276 (21), 251 (29), 234 (6), 188
(6), 160 (9), 142 (16), 114 (9), 110 (7), 82 (6), 69 (19), 45 (6),
39 (4). Anal. Calcd for C12H6ClNO3S2 (311.76): C, 46.23; H,
1.94; N, 4.49; Found: C, 46.18; H, 1.94; N, 4.56.
2.2.3.2. 6-tert-Butyl-2-(5-chloro-2,4-dihydroxyphenyl)-4H-
thieno[3,2-d][1,3]thiazin-4-one (2c). Yield: 78%, mp: 272–
274 C. 1H NMR (500 MHz, DMSO-d6) d: 12.18 (s, 1H,
C(20)-OH), 11.29 (s, 1H, C(40)-OH), 7.82 (s, 1H, C(30)-H),
7.61 (s, 1H, C(7)-H), 6.61 (s, 1H, C(60)-H), 1.43 (s, 9H, Me)
ppm; 13C NMR (125 MHz, DMSO-d6, d): 173.9, 167.6,
166.6, 158.4, 158.0, 156.0, 129.0, 123.7, 117.6, 112.9, 112.2,
104.3, 35.3, 31.3 (3C) ppm; IR (KBr): 3385 (OH), 2965
(CH), 2830 (CH), 1641 (C‚O), 1613 (C‚N), 1595 (C‚C),
1519 (C‚C), 1486, 1450, 1391, 1366, 1247 (CAOH), 1208,
1174, 1096, 1031, 916, 835, 811, 751, 714 cm1; EI-MS m/z
(%): 367 (M+, 100), 332 (28), 324 (43), 316 (17), 292 (11),
197 (8), 155 (4), 148 (3), 123 (3), 77 (2), 69 (12), 41 (6). Anal.
Calcd for C16H14ClNO3S2 (367.87): C, 52.24; H, 3.81; N,
3.82; Found: C, 52.34; H, 3.79; N, 3.83.
2.2.3.3. 2-(5-Ethyl-2,4-dihydroxyphenyl)-5-methyl-4H-thieno-
[2,3-d][1,3]thiazin-4-one (3c). Yield: 87%, mp: 272–273 C.
1H NMR (500 MHz, DMSO-d6) d: 11.65 (s, 1H, C(20)-OH),
10.49 (s, 1H, C(40)-OH), 7.53 (s, 1H, C(6)-H), 7.32 (s, 1H,
C(60)-H), 6.44 (s, 1H, C(30)-H), 2.48 (s, 2H, CH2Me), 2.46 (s,
3H, Me), 1.13 (t, J= 7.46 Hz, 3H, CH2Me) ppm; IR (KBr):
3418 (OH), 2959 (CH), 1626 (C‚O), 1531(C‚N), 1510
(C‚C), 1498 (C‚C), 1460, 1391, 1321, 1276, 1237 (CAOH),
1211, 1184, 1126, 1014, 977, 903, 874, 852, 784, 768 cm1;
13C NMR (125 MHz, DMSO-d6, d): 171.1, 167.1, 165.4,
161.7, 158.7, 134.2, 128.7, 124.0, 119.5, 119.2, 111.9, 103.2,
22.5, 17.6, 14.6 ppm; EI-MS m/z (%): 319 (M+, 100), 305
(M+-Me, 48), 261 (17), 256 (24), 244 (10), 181 (10), 165 (13),
128 (8), 69 (5), 64 (17). Anal. Calcd for C15H13NO3S2
(319.40): C, 56.41; H, 4.10; N, 4.45; Found: C, 54.97; H,
3.63; N, 4.65.
2.2.3.4. 2-(5-Chloro-2,4-dihydroxyphenyl)-5-methyl-4H-thieno-
[2,3-d][1,3]thiazin-4-one (4c). Yield: 83%, mp: 273–275 C.
1H NMR (500 MHz, DMSO-d6) d: 11.52 (s, 1H, C(20)-OH),ative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
http://dx.doi.org/10.1016/j.arabjc.2015.05.006
6 J. Matysiak et al.11.18 (s, 1H, C(40)-OH), 7.86 (s, 1H, C(60)-H), 7.38 (d,
J= 1.16 Hz, 1H, C(6)-H), 6.62 (s, 1H, C(30)-H), 2.47 (s, 3H,
Me) ppm; IR (KBr, m, cm1): 3399 (OH), 3320 (OH), 3149
(OH), 2830 (CH), 1618 (C‚O), 1532 (C‚N), 1500 (C‚C),
1441 (C‚C), 1386, 1346, 1232 (CAOH), 1208, 1179, 1059,
1032, 1018, 871, 848, 780, 757; 13C NMR (125 MHz,
DMSO-d6, d): 186.5, 167.4, 157.4, 154.4, 145.3, 135.3, 132.4,
123.7, 118.5, 114.4, 112.0, 103.8, 16.7 ppm; EI-MS m/z (%):
325 (M+, 100), 292 (19), 267 (30), 189 (10), 187 (25), 173
(15), 171 (43), 155 (14), 139 (10), 131 (6), 95 (6), 69 (10), 45
(8). Anal. Calcd for C13H8ClNO3S2 (325.79): C, 47.93; H,
2.48; N, 4.30; Found: C, 48.02; H, 2.44; N, 4.36.
2.2.4. A general procedure for the synthesis of compounds 1d,
1e–4e
A mixture of 4-amino-1H-imidazole-5-carboxamide (1d) or the
corresponding aminopyrazolecarboxamide (1e–4e) and elec-
trophile STB (1.5 mmol) in MeOH (8 mL) (Scheme 3) was
treated to reﬂux for 2.5–3 h. The hot mixture was ﬁltered via
a Bu¨chner funnel. The ﬁltrate was concentrated and the
formed solid was ﬁltered off (compounds 1d, 1e, 3e, 4e) or
the reaction mixture was left at room temperature (24 h) and
ﬁltered (2e). The compounds were crystallized from MeOH
(5 mL).
2.2.4.1. 5-(2,4-Dihydroxyphenyl)imidazo[4,5-d][1,3]thiazin-
7(1H)-one (1d). Yield: 81%, mp: 334–335 C. 1H NMR
(500 MHz, DMSO-d6) d: 13.44 (s, 1H, NH), 11.74 (s, 1H,
C(20)-OH), 10.23 (s, 1H, C(40)-OH), 8.23 (d, J= 9.1 Hz, 1H,
C(60)-H), 7.48 (s, 1H, C(2)-H), 6.39 (m, 2H, C(30,50-H) ppm;
IR (KBr): 3478 (OH), 3372 (OH), 3127 (OH), 1643 (C‚O),
1585 (C‚N), 1500 (C‚C), 1459, 1390, 1353, 1272 (CAOH),
1214, 1115, 1058, 989, 965, 940, 826, 801, 779, 723 cm1; 13C
NMR (125 MHz, DMSO-d6) d: 165.4, 163.0, 156.7, 143.5,
136.5, 134.0, 130.6, 120.7, 117.0, 108.8, 102.6 ppm; EI-MS
m/z (%): 261 (M+, 100), 244 (18), 2334 (9), 228 (7), 203 (9),
172 (7), 153 (100), 143 (9), 137 (22), 126 (9), 120 (11), 110
(14), 97 (11), 81 (7), 69 (10), 53 (7), 44 (8), 39 (5). Anal.
Calcd for C11H7N3O3S (261.18): C, 50.58; H, 2.68; N, 16.08;
Found: C, 50.64; H, 2.71; N, 16.02.
2.2.4.2. 6-(2,4-Dihydroxyphenyl)pyrazolo[3,4-d][1,3]thiazin-
4(2H)-one (1e). Yield: 72%, mp: 271–272 C. 1H NMR
(500 MHz, DMSO-d6) d: 14.26 (s, 1H, NH), 12.11 (s, 1H,
C(20)-OH), 10.57 (s, 1H, C(40)-OH), 8.18 (s, 1H, C(3)-H),
7.70 (d, J= 8.58 Hz, 1H, C(60)-H), 7.63 (d, J= 8.56 Hz,
1H, C(50)-H), 6.47 (d, J= 8.36 Hz, 1H, C(30)-H) ppm; 13C
NMR (125 MHz, DMSO-d6) d: 165.3, 165.2, 163.9, 161.1,
149.8, 134.0, 130.8, 111.6, 109.5, 107.7, 101.2 ppm; IR (KBr):
3443 (OH), 3182 (OH), 3112 (OH), 2923 (CH), 2851 (CH),
1657 (C‚O), 1573 (C‚N), 1531 (C‚C), 1481, 1331, 1248
(CAOH), 1198, 1168, 1136, 1076, 983, 936, 888, 848, 778,
754, 706 cm1; EI-MS m/z (%): 261 (M+, 100), 244 (5), 233
(6), 203 (10), 192 (25), 153 (11), 137 (19), 125 (6), 108 (8), 97
(5), 80 (3), 69 (8), 52 (6), 45 (3), 39 (7). Anal. Calcd for
C11H7N3O3S (261.26): C, 50.57; H, 2.70; N, 16.08; Found:
C, 50.65; H, 2.66; N, 15.99.
2.2.4.3. 6-(2,4-Dihydroxyphenyl)-1-phenylpyrazolo[3,4-d]
[1,3]thiazin-4(1H)-one (2e). Yield: 81%, mp: 300–303 C.
1H NMR (500 MHz, DMSO-d6) d: 11.79 (s, 1H, C(20)-OH),Please cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolife
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),10.64 (s, 1H, C(40)-OH), 8.47 (s, 1H, C(3)-H), 7.85 (m, 2H,
C(Ar)-H), 7.75 (d, J= 8.89 Hz, 1H, C(60)-H), 7.65 (t,
J= 7.6 Hz, 2H, C(Ar)-H), 7.55 (t, J= 7.40 Hz, 1H, C(Ar)-
H), 6.47 (dd, J= 8.82 and 2.25 Hz, 1H, C(50)-H), 6.36 (d,
J= 2.24 Hz, 1H, C(30)-H) ppm; IR (KBr): 3420 (OH), 3315
(OH), 2638 (CH), 2822 (CH), 1641 (C‚O), 1628 (C‚N),
1572 (C‚N), 1523 (C‚C), 1511 (C‚C), 1487, 1440, 1365,
1269, 1236 (CAOH), 1193, 1168, 1147, 1118, 1038, 966, 934,
920, 895, 847, 786, 760, 739, 711 cm1; EI-MS m/z (%): 337
(M+, 100), 304 (6), 279 (13), 268 (31), 201 (21), 172 (5), 153
(12), 137 (21), 103 (5), 91 (7), 77 (20), 69 (5), 51 (10), 44 (24),
40 (62). Anal. Calcd for C17H11N3O3S (337.35): C, 60.52; H,
3.29; N, 12.45; Found: C, 60.62; H, 3.23; N, 12.51.
2.2.4.4. 6-(5-Ethyl-2,4-dihydroxyphenyl)-1-phenylpyra-
zolo[3,4-d][1,3]thiazin-4(1H)-one (3e). Yield: 71%, mp:
217–219 C. 1H NMR (500 MHz, DMSO-d6,) d: 11.63 (s,
1H, C(20)-OH), 10.65 (s, 1H, C(40)-OH), 8.45 (s, 1H, C(3)-
H), 7.85 (m, 2H, C(Ar)-H), 7.65 (m, 3H, C(Ar)-H), 7.55 (m,
1H, C(Ar)-H), 6.64 (s, 1H, C(30)-H), 2.48 (q, 2H, CH2Me),
1.13 (t, 3H, J= 7.48 Hz, CH2Me) ppm;
13C NMR
(125 MHz, DMSO-d6) d: 176.7, 166.6, 160.8, 160.0, 149.7,
139.4, 138.7, 129.8 (2C), 127.5, 124.7, 123.5 (2C), 115.6,
112.5, 104.9, 98.0, 22.3, 14.3 ppm; IR (KBr): 3251 (OH),
2954 (CH), 1661 (C‚O), 1629 (C‚N), 1596 (C‚N), 1520
(C‚C), 1391, 1334, 1279, 1243 (CAOH), 1214, 1128, 1032,
944, 890, 871, 838, 806, 774, 756, 728 cm1; EI-MS m/z (%):
365 (M+, 100), 350 (M-Me, 70), 308 (3), 296 (15), 290 (2),
203 (3), 165 (5), 149 (2), 103 (2), 91 (3), 77 (12), 51 (3). Anal.
Calcd for C19H15N3O3S (365.41): 62.45; H, 4.14; N, 11.50;
Found: C, 62.55; H, 4.08; N, 11.57.
2.2.4.5. 6-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylpyra-
zolo[3,4-d][1,3]thiazin-4(1H)-one (4e). Yield: 87%, mp:
308–309 C. 1H NMR (500 MHz, DMSO-d6) d: 11.68 (s, 1H,
C(20)-OH), 11.60 (s, 1H, C(40)-OH), 7.92 (s, 1H, C(3)-H),
7.91 (s, 1H, C(60)-H), 7.57 (m, 4H, C(Ar)-H), 7.38 (t,
J= 7.2 Hz, 1H, C(6)-H, 6.64 (s, 1H, C(30)-H) ppm; 13C
NMR (125 MHz, DMSO-d6) d: 176.7, 169.7, 159.0, 158.8,
152.2, 138.0, 135.9, 130.3, 129.8 (2C), 129.0, 124.6 (2C),
114.3, 112.9, 105.4, 104.6 ppm; IR (KBr): 3439 (OH), 3324
(OH), 3138 (OH), 2960 (CH), 2835 (CH), 1635 (C‚O), 1612
(C‚N), 1567 (C‚N), 1550 (C‚C), 1514 (C‚C), 1501
(C‚C), 1462, 1438, 1339, 1254, 1220 (CAOH), 1181, 1152,
1104, 1021, 953, 927, 891, 845, 779, 753, 731 cm1; EI-MS
m/z (%): 371 (M+, 100), 336 (19), 313 (4), 294 (8), 268 (3),
201 (10), 187 (8), 171 (13), 147 (4), 103 (4), 91 (5), 77 (20),
51 (7). Anal. Calcd for C17H10ClN3O3S (371.80): C, 54.92;
H, 2.71; N, 11.30; Found: C, 55.02; H, 2.71; N, 11.23.
2.2.5. A general procedure for the synthesis of compounds 1f-3f
A mixture of 3-aminobenzofuran-2-carboxamide (1.4 mmol)
and the corresponding electrophile STB (1.4 mmol) in
MeOH (4 mL) (Scheme 4) was treated to reﬂux for 2.5–3.5 h.
The hot mixture was ﬁltered via a Bu¨chner funnel and the solid
formed during the synthesis was combined with that obtained
after the ﬁltrate concentration (1e). In the case of compounds
2e and 3e the reaction mixture was left at room temperature
(24 h) and ﬁltered. The compounds were crystallized from
MeOH (4 mL) (compounds 1e, 2e) or from MeOH/H2O (1:1,
4 mL) (3e).rative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
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thiazin-4-one (1f). Yield: 73%, mp: 279–281 C. 1H NMR
(500 MHz, DMSO-d6) d: 11.62 (s, 1H, C(20)-OH), 10.23 (s,
1H, C(40)-OH), 8.20 (d, J= 9.44 Hz, 1H, C(Ar)-H), 7.82 (m,
2H, C(Ar)-H), 7.65 (m, 2H, C(Ar)-H), 7.48 (m, 1H, C(Ar)-
H, 6.40 (m, 2H, C(30,50)-H) ppm; 13C NMR (125 MHz,
DMSO-d6) d: 170.3, 169.4, 163.5, 160.3, 160.2, 155.0, 143.4,
134.0, 131.5, 130.3, 124.8, 122.4, 121.6, 112.9, 111.8, 109.2,
103.1 ppm; IR (KBr): 3444 (OH), 3334 (OH), 3167 (OH),
1653 (C‚O), 1631 (C‚N), 1593 (C‚N), 1578 (C‚C),
1493, 1469, 1428, 1370, 1349, 1331, 1283, 1234 (CAOH),
1193, 1128, 987, 948, 915, 849, 791, 744 cm1; EI-MS m/z
(%): 371 (M+, 100), 296 (4), 283 (9), 251 (10), 242 (18), 222
(10), 195 (6), 176 (5), 153 (4), 141 (6), 137 (6), 120 (25), 103
(5), 88 (6), 76 (5), 62 (5). 51 (4), 39 (7). Anal. Calcd for
C17H10ClN3O3S (371.80): C, 61.73; H, 2.91; N, 4.50; Found:
C, 61.80; H, 2.89; N, 4.56.
2.2.5.2. 2-(5-Ethyl-2,4-dihydroxyphenyl)-4H-benzofuro[3,2-
d][1,3]thiazin-4-one (2f). Yield: 84%, mp: 286–287 C. 1H
NMR (500 MHz, DMSO-d6) d: 12.13 (s, 1H, C(20)-OH),
10.59 (s, 1H, C(40)-OH), 8.16 (d, J= 7.8 Hz, 1H, C(9)-H),
8.10 (s, 1H, C(60)-H), 7.88 (d, J= 8.48 Hz, 1H, C(6)-H),
7.79 (td, J= 7.23 and 1.16 Hz, 1H, C(8)-H), 7.58 (t,
J= 7.27 Hz, 1H, C(7)-H), 6.49 (s, 1H, C(30)-H), 2.54 (q,
J= 7.5 Hz, 2H, CH2Me), 1.15 (t, J= 7.5 Hz, 3H, CH2Me)
ppm; IR (KBr): 3295 (OH), 3206 (OH), 1662 (C‚O), 1640
(C‚N), 1588 (C‚N), 1530 (C‚C), 1502 (C‚C), 1487,
1470, 1441, 1381, 1350, 1329, 1264, 1228 (CAOH), 1187,
1135, 996, 938, 867, 851, 735 cm1; EI-MS m/z (%): 339
(M+, 100), 324 (M+ -Me, 80), 296 (12), 270 (23), 264 (23),
165 (5), 145 (5), 120 (10), 69 (10). Anal. Calcd for
C18H13NO4S (339.37): C, 63.71; H, 3.86; N, 4.13; Found: C,
63.46; H, 3.84; N, 4.15.
2.2.5.3. 2-(5-Chloro-2,4-dihydroxyphenyl)-4H-benzofuro[3,2-
d][1,3]thiazin-4-one (3f). Yield: 87%, mp: 291–293 C. 1H
NMR (500 MHz, DMSO-d6) d: 11.83 (s, 1H, C(20)-OH),
11.27 (s, 1H, C(40)-OH), 8.23 (d, J= 7.59 Hz, 1H, C(9)-H),
8.04 (s, 1H, C(60)-H), 7.88 (d, J= 8.48 Hz, 1H, C(6)-H),
7.79 (td, J= 7.25 and 1.21 Hz, 1H, C(8)-H), 7.58 (t,
J= 7.23 Hz, 1H, C(7)-H), 6.67 (s, 1H, C(30)-H) ppm; IR
(KBr): 3228 (OH), 3257 (OH), 1661 (C‚O), 1628 (C‚N),
1583 (C‚N), 1557 (C‚C), 1481, 1470, 1419, 1367, 1322,
1273, 1229 (CAOH), 1198, 1125, 990, 953, 907, 853, 786,
732 cm1; EI-MS m/z (%): 345 (M+, 100), 317 (14), 310
(25), 301 (9), 285 (12), 256 (10), 229 (5), 175 (9), 142 (6), 120
(24), 88 (8), 69 (9), 51 (4). Anal. Calcd for C16H8ClNO4S
(345.76): C, 55.58; H, 2.33; N, 4.05; Found: C, 55.66; H,
2.34; N, 4.03.
2.3. Antiproliferative assay in vitro
There were applied the following human cell lines established
in vitro: T47D (breast cancer), SW707 (rectal adenocarci-
noma), A549 (nonsmall cell lung carcinoma) from the
American Type Culture Collection (Rockville, Maryland,
U.S.A.) and HCV29T (bladder cancer) from the Fibiger
Institute, Copenhagen, Denmark. Twenty-four hours before
the addition of the tested agents, the cells were plated in 96-
well plates (Sarstedt Inc, Newton, NC, USA) at a density ofPlease cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolifer
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),104 cells/well. All cell lines were maintained in the opti-MEM
medium supplement with 2 mM glutamine (Gibco, Warsaw,
Poland), streptomycin (50 lg/mL), penicillin (50 U/mL)
(Polfa, Tarchomin, Poland) and 5% foetal calf serum
(Gibco, Grand Island, USA). The cells were incubated at
37 C in the humid atmosphere saturated with 5% CO2. The
solutions of compounds (l mg/mL) were prepared ex tempore
by dissolving the substance in 100 lL of DMSO completed
with 900 lL of tissue culture medium. Afterwards, the com-
pounds were diluted in the culture medium to reach the ﬁnal
concentrations ranging from 0.1 to 100 lg/mL. The solvent
(DMSO) used at the highest concentration in the test did not
reveal any cytotoxic activity. Cisplatin was applied as a test
referential agent. The cytotoxicity assay was performed after
72 h exposure of the cultured cells at the concentration ranging
from 0.1 to 100 lg/mL of the tested agents. The SRB test mea-
suring the cell proliferation inhibition in the in vitro culture
was applied. The cells attached to the plastic were ﬁxed with
cold 50% TCA (trichloroacetic acid, Sigma–Aldrich Chemie
GmbH, Steinheim, Germany) added on the top of the culture
medium in each well. The plates were incubated at 4 C for 1 h
and then washed ﬁve times with tap water. The background
optical density was measured in the wells ﬁlled with the med-
ium, without the cells. The cellular material ﬁxed with TCA
was stained with 0.4% sulforhodamine B (Chemie GmbH,
Steinheim, Germany) dissolved in 1% acetic acid (POCh,
Gliwice, Poland) for 30 min. The unbound dye was removed
by rinsing (four times) with 1% acetic acid, and the protein-
bound dye was extracted with 10 mM unbuffered Tris base (t
ris(hydroxymethyl)aminomethane, POCh, Gliwice, Poland)
for determination of optical density (at 540 nm) in a
computer-interfaced, 96-well microtiter plate reader Uniskan
II (Labsystems, Helsinki, Finland). The compounds were
tested in triplicates per experiment. The experiments were
repeated at least 3 times. The IC50 values were calculated by
Cheburator 0.9.0 software.
2.4. In silico ADMET evaluations
In silico ADMET evaluation of compounds was performed by
the ADMET Predictor version 7.1 (Admet 2014a). Structures
of the compounds were saved as the mol ﬁle and they were
uploaded into the ADMET predictor software for further eval-
uations. All parameters were calculated at pH 7.4.
3. Results and discussion
3.1. Chemistry
4H-3,1-benzothiazin-4-ones as a leading group of compounds
(a) were prepared from 2-amino-N-phenylbenzamides (2a,
5a–9a) or 2-amino-N-methylbenzohydrazide (1a, 3a, 4a) and
the corresponding electrophile (STB) (Scheme 1). In the syn-
thesis de novo of sulphur analogues 4H-3,1-benzothiazine-4-
thiones (b) 2-amino-N-phenylbenzothioamide was applied
(Scheme 1). The 13C NMR spectra of compounds a show a
low ﬁeld signal at 182–181 ppm which can be attributed to car-
bon atom of C‚O group. In the case of compounds b C‚S
group is registered at 210 ppm. The IR spectra of compounds
a exhibit a strong band in the range of 1674–1642 cm1 of
m(C‚O). Next we made an attempt to obtain someative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
http://dx.doi.org/10.1016/j.arabjc.2015.05.006
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8 J. Matysiak et al.heterocyclic analogues of benzothiazin-4-one to ﬁnd the inﬂu-
ence on antiproliferative activity of molecule size, the presence
and localization of additional heteroatoms in a heterocycle
fused to thiazin-4-one. 4H-Thieno[3,2-d][1,3]thiazin-4-ones
(1c and 2c) were obtained from 3-aminothiophene-
2-carboxamide, but in a different manner conﬁgured 4H-
thieno[2,3-d][1,3]thiazin-4-ones (3c and 4c) from properly
substituted 2-aminothiophene-3-carboxamide (Scheme 2). In
the 1HNMR spectra, the thienothiazinone ring proton of com-
pounds 2c and 3c gives a singlet at 7.6 and 7.5 ppm, respec-
tively. Two nitrogen atoms of various positions were
introduced in the form of fused to thiazin-4-one eitherPlease cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolife
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),imidazole (d) or pyrazole (e) ring (Scheme 3). In compounds
2e–6e0, the acidic = NH proton of the pyrazole moiety was
substituted by the phenyl ring or Me substituent (Scheme 3).
In this way the compounds of higher lipophilicity were
obtained. 1HNMR spectra give signals in the range of 14.26–
13.44 ppm which is attributed to the NH proton. The CH pro-
ton of imidazo[4,5-d][1,3]thiazin-7(1H)-one and pyra-
zolo[1,3]thiazinones appears as a singlet at 7.5 and in the
range of 8.5–7.9 ppm respectively. To increase signiﬁcantly
the size of the molecule and its shape as well as add another
heteroatom we obtained 3 analogues of 4H-benzofuro[3,2-
d][1,3]thiazin-4-one (f) (Scheme 4). The IR spectra ofrative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
http://dx.doi.org/10.1016/j.arabjc.2015.05.006
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Design, synthesis and antiproliferative activity against human cancer cell lines 9compounds f exhibit a strong band in the range of 1662–
1654 cm1 of m(C‚O). In the IR spectra of all compounds a
broad strong band in the range of 3500–3100 cm1 of m(O-
H) is registered. In the synthesis we concentrated on the com-
pounds with Et or Cl substituents in benzenediol moiety
because it is generally believed that this type of substitution
has a beneﬁcial effect on the anticancer activity (McDonald
et al. 2006; Niewiadomy et al., 2011). Electrophiles (STB)
(Schemes 1–4) as initial compounds were obtained from prop-
erly substituted resorcinols and SOCl2 in the diethyl ether med-
ium (Matysiak and Niewiadomy, 2006). The compounds were
obtained according to the elaborated by our team synthesis
method preliminary used for the synthesis of 4H-3,1-
benzothiazin-4-ones (Matysiak et al., 2012) and next applied
for the preparations of some thienothiazinones (Matysiak
et al., 2015a) and azolothiaziones (Matysiak et al., 2015b).
At present we optimized synthesis conditions for a much
broader spectrum of nucleophilic reagents and we concen-
trated on the ethyl and chlorine substituted benzenediols.
3.2. Antiproliferative activity
The compounds presented in Schemes 1–4 have been evaluated
for their antiproliferative activities against human bladder can-
cer HCV29T cells. For this purpose, the SRB assay was used
(Skehan et al., 1990). The cytotoxic activity in vitro was
expressed as IC50 – the concentration of a compound to inhibit
proliferation rate of the tumour cells by 50% as compared to
the untreated cells. The results of screening are collected in
Table 1. The selected compounds of the highest activity against
HCV29T were also tested against human non-small cell lung
carcinoma A549, human breast cancer T47D and human rectalTable 1 Antiproliferative activity of compounds against
human bladder cancer cell line HCV29T expressed as IC50
a.
No. IC50 (lM) No. IC50 (lM)
1a 54.83 ± 7.51 1c0 66.49 ± 6.45
2a 46.98 ± 23.99 3c0 69.95 ± 8.48
3a 35.14 ± 11.59 1d 322.27 ± 57.66
4a 24.37 ± 7.78 1d0 106.91 ± 3.97
5a 74.53 ± 14.58 1e 71.33 ± 29.86
6a n.a.b 1e0 34.81 ± 7.22
1b 68.48 ± 14.48 5e0 26.06 ± 7.81
Cisplatin 6.43 ± 1.20 1f 20.37 ± 4.78
a IC50 indicates the compound concentration (lM) that inhibits
the proliferation rate of tumour cells by 50% as compared to the
untreated control cells. The values are the means ± SD of 9 inde-
pendent experiments.
b n.a. – activity above studied concentrations.
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the derivatives of the 4H-thieno[3,2-d][1,3]thiazin-4-one (2c)
and 1-phenylpyrazolo[3,4-d][1,3]thiazin-4(1H)-one (3e, 4e)
type were the most active compounds against all studied cells.
In particular interesting is 2-(5-chloro-2,4-dihydroxyphenyl)-
4H-benzofuro[3,2-d][1,3]thiazin-4-one (3f) of very high activity
towards HCV29T cells (IC50 = 2.05 lM). The antiprolifera-
tive action of the most active compounds is comparable or
stronger than that of cisplatin evaluated comparatively.
3.3. QSAR analysis
For more comprehensive structure–activity elucidation some
previously described compounds were also studied under the
same biological condition and included in the analysis
(Matysiak et al., 2015a; Matysiak et al., 2015b). The results
show that the activity of compounds signiﬁcantly depends on
the kind of heterocyclic skeleton as well as on substitution pat-
tern of both heterocyclic and phenyl rings. The analysis shows,
that in the group of benzothiazin-4-ones (a), the beneﬁcial
inﬂuence on the activity is exhibited by a chlorine atom in
the heterocyclic ring (Table 1) (7a, 8a, 9a). The lowest antipro-
liferative effect for the compounds with a ﬂuorine atom (5a
and 6a) was detected. In the group of the analogues with
unsubstituted benzothiazin-4-one ring, the presence of Et or
chlorine atom in the benzenediol moiety increases their
antiproliferative potency (3a, 4a). This effect of compound
9a against all studied cells was also observed. Replacing of
C‚O group with C‚S one gave compounds of higher activi-
ties against all studied cell lines (3a and 2b). For compound
with the Et substituent more beneﬁcial properties were found
compared to the unsubstituted analogue, according to the
overall trend. Considering replacement of the benzothiazin-4-
one ring with the thienothiazinone one, it can be observed that
this modiﬁcation is beneﬁcial for anticancer potency (4a
compared to 1c). In the group of differently conﬁgured
thienothiazinones, the most active ones are compounds with
the tert-butyl substituent (2c and 2c0). In this group also a ben-
eﬁcial inﬂuence of the presence of chlorine atom in the ben-
zenediol moiety on the antiprolifertive potency is observed
(1c0, 3c0 against HCV29T, 2c0 against all studied cell lines).
Replacement of the benzothiazin-4-one ring by imidazothiazi-
none one produced the compounds of the lowest potency in
the considered group of analogues (1d, 1d0), however, a
beneﬁcial effect on activity of Et substituent insertion was con-
ﬁrmed. Pyrazolothiazinones showed a low activity (1e and 1e0)
but higher compared to imidazo[4,5-d][1,3]thiazin-7(1H)-one.
N-alkyl(aryl) substitution on the pyrazole ring produced com-
pounds of signiﬁcantly higher activity, especially in the case of
the presence of a phenyl ring (compounds 2e–4e). In the group
of pyrazolothiazinones all ethyl analogues were more activeative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
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Table 2 Antiproliferative activity of selected compounds against the human cancer cells: bladder HCV29T, non-small lung carcinoma
A549, breast T47D and rectal adenocarcinoma SW707 expressed as IC50
a.
No. Line/IC50 (lM)
HCV 29T A549 T47D SW 707
7a 16.01 ± 3.94 21.20 ± 1.72 13.10 ± 3.38 21.00 ± 8.69
8a 19.60 ± 1.59 12.86 ± 0.75 9.98 ± 3.96 29.37 ± 1.71
9a 14.46 ± 8.17 16.40 ± 9.58 8.05 ± 2.52 15.40 ± 4.03
2b 16.36 ± 3.58 21.24 ± 10.21 14.00 ± 0.38 14.84 ± 2.44
1c 10.52 ± 1.44 15.65 ± 3.59 10.33 ± 1.83 16.62 ± 4.30
2c 5.79 ± 0.76 8.59 ± 0.71 5.38 ± 2.01 8.45 ± 4.05
4c 15.16 ± 7.52 9.64 ± 1.72 16.21 ± 4.39 13.72 ± 1.96
2c0 15.38 ± 0.72 19.13 ± 9.58 13.71 ± 6.32 9.66 ± 2.19
2e 18.91 ± 4.30 16.39 ± 4.83 9.46 ± 1.57 21.37 ± 4.83
3e 8.98 ± 2.52 9.55 ± 2.96 12.62 ± 5.83 9.41 ± 3.94
4e 6.29 ± 2.34 11.22 ± 3.33 6.64 ± 0.75 7.77 ± 2.04
6e0 17.60 ± 2.89 13.52 ± 1.22 9.23 ± 7.79 21.13 ± 7.64
2f 9.19 ± 2.30 10.25 ± 5.36 13.94 ± 2.59 7.25 ± 0.50
3f 2.05 ± 0.90 11.94 ± 0.46 5.61 ± 0.64 9.40 ± 3.35
Cisplatin 6.43 ± 1.20 11.60 ± 0.77 14.89 ± 3.90 13.30 ± 1.71
a IC50 indicates the compound concentration (lM) that inhibits the proliferation rate of tumour cells by 50% as compared to the untreated
control cells. The values are the means ± SD of 9 independent experiments.
10 J. Matysiak et al.than that unsubstituted ones. The chlorine analogue (4e) was
the most active. In the group of 4H-benzofuro[3,2-d][1,3]thia-
zin-4-ones (f) the compound with unsubstituted benzenediol
moiety is also signiﬁcantly less active. The activity of other
compounds was higher and in some cases similar to that of cis-
platin. 3f is the most active compound against HCV29T cells.
3.4. In silico ADME/Toxicity evaluations
Not satisfactory ADME/Toxicity properties of compounds are
a major reason for drug candidate failure in drug development.
Therefore, there is a great interest of scientists in developing
predictive in silico models which may be used in the initial
stage of the drug candidate development (Guerra et al.,
2010). For the evaluation of compounds ADMET properties,
ADMET Predictor version 7.1 was used in this paper
(Admet 2014a). The selected compounds, mainly of the highestTable 3 Molecular descriptors and parameters characterizing ads
estimated using ADMET Predictor software.
No. PSA
(A˚2)
Log D Mlog P Rule of 5 nRB S (lg/mL) P
(c
7a 70.4 3.67 2.33 0 1 24.2 5
8a 70.4 3.98 2.58 0 2 20.1 5
9a 70.4 3.48 2.33 0 1 19.3 6
2b 70.4 3.96 2.87 0 2 5.26 7
2c 70.4 4.36 2.58 0 2 10.0 4
3c 70.4 3.59 2.08 0 2 18.7 5
4c 70.4 2.97 1.83 0 2 20.2 5
1d 53.4 1.1 0.26 0 1 47.4 2
2e 70.4 2.56 2.02 0 2 37.2 4
3e 70.4 3.11 2.49 0 3 30.3 4
4e 70.4 2.85 2.26 0 2 30.8 5
2f 99.1 3.76 1.88 0 2 13.1 4
3f 99.1 3.36 1.64 0 1 12.9 5
a PSA – polar surface area; Log D – octanol–water distribution coefﬁcie
rotatable bonds: S – water solubility: Peff – human jejunal effective perm
Kidney (MDCK) cells; Vd – volume of distribution; BBB – qualitative
logarithm of the brain/blood partition coefﬁcient: unbd – overall fractio
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drug-like properties of compounds relatively simple parame-
ters such: molecular weight (M), hydrophobicity: log D, log
P, a number of hydrogen bonding atoms (HBD, HBA) and
Lipinski’s rule of ﬁve were used (Lipinski et al., 1997). The
results collected in Table 3 show, that all analysed compounds
fulﬁl this criterion (rule of 5–0). Compounds obey the Oprea’s
criteria. They possess 1–4 rotatable bonds (nRB) (less than 10),
so they are conformationally stable and their polar surface
area (PSA) is in the range of 53.4–99.1 A˚2 (lower than
120 A˚2) (Oprea et al., 2000). Additionally good water solubility
(>10 lg/mL) for the compounds is predicted (except for 2b)
(Kerns et al., 2008). The data exhibit that the analysed com-
pounds are drug-like, and there is a signiﬁcant probability that
compounds might have favourable pharmacokinetics after oral
administration (Lipinski 2000). The analysis of the more
advanced parameters of adsorption process prediction: theorption and distribution processesa of the selected compounds
eﬀ
m/s · 104)
MDCK
(cm/s · 107)
Vd (L/kg) BBB Log
BB
Unbd
(%)
.65 296.12 0.86 Low 0.17 2.16
.36 290.16 0.95 Low 0.19 1.9
.39 344.45 0.29 Low 0.21 0.46
.61 240.11 0.75 Low 0.16 2.36
.56 257.7 0.46 Low 0 0.64
.51 203.2 0.79 Low 0.03 2.43
.98 249.35 0.26 Low 0.38 0.68
.32 123.02 0.69 Low 0.43 10.09
.93 156.77 0.85 Low 0.12 3.6
.72 179.21 0.98 Low 0.14 2.72
.29 230.14 0.39 Low 0.31 0.84
.59 230.48 0.95 Low 0.12 1.77
.17 286.42 0.34 Low 0.46 0.52
nt; M log P – log P according to Moriguchi model; nRB – number of
eability; MDCK – apparent permeability for Madin-Darby Canine
likelihood high/low of crossing the blood–brain barrier; Log BB –
n of a drug unbound in human blood plasma (in%).
rative activity against human cancer cell lines of novel benzo-, benzofuro-, azolo-
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Table 4 Characteristics of metabolism and toxicitya of the selected compounds in silico by the ADMET Predictor software.
No. Substr. of
CYP1A2/clint
(lL/min/mg)
Substr. of
CYP2C9/clint
(lL/min/mg)
TOX RAT (mg/kg) TOX Risk/TOX code ADMET Risk code ADMET Risk
7a Yes (63%) 32.7 Yes (58%) 92.6. 872.87 1/Mu ow, fu, Mu, 1A, C9 3.58
8a Yes (60%) 13.5 Yes (56%) 11.1 916.47 2/Hp, Mu ow, fu, Hp, Mu, C9 4.03
9a Yes (63%) 59.4 Yes (75%) 10.6 474.74 1/Hp fu, Hp, 1A, C9 4
2b Yes (80%) 10.9 Yes (75%) 16.7 1041.21 1.07/Xm, Hp ow, Sw, fu, Xm, Hp, C9 3.52
2c Yes (55%) 19.5 Yes (58%) 15.2 479.08 1/Hp ow, fu, Hp, 1A, C9 4.16
3c Yes (63%) 49.2 Yes (53%) 15.2 988.24 2/Hp, Mu ow, fu, Hp, Mu, C9 3.37
4c Yes (57%) 14.6 Yes (63%) 61.9 252.24 1.56/ra, Hp fu, ra, Hp, C9 3.56
1d Yes (63%) 43.2 Yes (63%) 12.4 1044.25 1/Hp Hp 1
2e Yes (57%) 26.8 No (65%) – 1205.85 3/Xm, Hp, Mu Xm, Hp, Mu 3
3e Yes (55%) 59.1 No (71%) – 1189.38 3/Xm, Hp, Mu fu, Xm, Hp, Mu 3.14
4e Yes (58%) 79.7 Yes (58%) 31.5 639.43 3/Xm, Hp, Mu fu, Xm, Hp, Mu, C9 5
2f Yes (55%) 51.3 No (73%) – 734.17 2/Hp, Mu ow, fu, Hp, Mu, ti 2.97
3f Yes (57%) 26.5 Yes (75%) 94.9 308.17 2.1/ra, Hp, Mu fu, ra, Hp, Mu, 1A, C9 4.87
a Xm – carcinogenicity in chronic mouse studies; Hp – hepatotoxicity; Mu – TOX MUT Risk > 1; Ra – TOX RAT< 320 (acute toxicity in
rats); Xm – TOX BRM Mouse < 35 (carcinogenicity in chronic mouse studies); fu:% Unbnd < [1, 3] (low fraction unbound in plasma); Vd:
Vd > [3.7, 5.7] (high steady-state volume of distribution); ow: log P> [4.5, 5.5] or log D> [3.5, 4.5] or Mlog P> [3.7, 4.3] (high log P o /w);
1A – MET 1A2 Km > 0.01 lM and MET 1A2 CLint > [15,30]; C9: MET 2C9 Km> 0.01 lM and MET 2C9 CLint > [15,30 lL/min/mg]; ti:
MET 3A4 Ki tes < 1.0 and (MET 3A4 I tes = Yes or MET 3A4 Inh = Yes); SG – TOX SGOT= Toxic and TOX SGPT= Toxic (SGOT and
SGPT elevation); Sw: S < [0.003, 0.010 g/mL] (low solubility).
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meability (Papp) for Madin-Darby Canine Kidney (MDCK)
shows that for most of the studied compounds a medium per-
meability is predicted (Table 3). Their MDCK is in the range
of 25–500 · 107 cm/s and Peff is >4 · 104 cm/s (except for
1d and 1e) (Irvine et al., 1999). The unbd parameter, which
reﬂects the overall fraction of a drug unbound in human blood
plasma (in%) is rather low. Two derivatives have a very weak
afﬁnity for human blood proteins (1d, 1e). The calculated distri-
bution volume (Vd) is in the range of 0.22–0.98 L/kg (Table 3).
BBB ﬁltering (qualitative likelihood high/low of crossing the
blood–brain barrier (BBB)) and log BBB (logarithm of the
brain/blood partition coefﬁcient) were estimated to predict
the BBB penetration. According to the calculated values
(Table 3) all compounds show low brain penetration
(BBB < 0.19) and they do not rather pass across the BBB.
Taking this into account the compounds are not recommended
as CNS active agents (Ma et al., 2005). For the prediction of
compounds metabolism CYP 1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1, and 3A4 enzymes in human were taken into
consideration (Guengerich 2008). The data collected in
Table 4 show, that all derivatives may be substrates of CYP
1A2 and the majority of 2C9. Intrinsic clearances (Clint) due
to metabolism mediated by both enzymes are also calculated.
Compounds show middle toxicity in the range of 474–
1205 mg/kg predicted for rats after oral administration. In this
area only for 4c not satisfactory result was calculated (Zhu
et al., 2009). The global ADMET Risk of the compounds
was also estimated (Table 4). The algorithm elaborated by
Simulations Plus using a reﬁned subset of WDI was applied
(Admet 2014b). That characteristic obeys 24 different rules,
including risk rules connected with oral absorption in human,
toxicity, metabolic potency and additional two rules: low frac-
tion unbound in plasma (Unbnd < [1,3]) and high steady-state
volume of distribution (Vd > [3.7,5.7]). The considered com-
pounds possess global ADMET Risk in the range of 1–5. It
is greater than 6.5 for about 10% of the focused WDI
(Admet 2014b). Clearly the lowest risk for 1d was predicted.Please cite this article in press as: Matysiak, J. et al., Design, synthesis and antiprolifer
and thieno-1,3-thiazinone resorcinol hybrids. Arabian Journal of Chemistry (2015),Relatively high toxicity for active compounds 2e, 3e and 4e
was estimated and slightly lower for 3f. For the most active
compound 2c the lowest toxicity in the analysed group of
derivatives was predicted. Its relatively high ADMET risk
parameter is connected mainly with metabolism. Toxicities
are the principle problem in the drug design and therefore, this
compound may be subjected to further testing as a potential
anticancer agent.
4. Conclusion
New compounds of benzothiazin-4-one type and its hetero-
cyclic analogues were obtained according to the one-step syn-
thesis method elaborated by us. SAR analysis reveals that the
most active compounds are those with a 4H-thieno[3,2-
d][1,3]thiazin-4-one and benzofuro[3,2-d][1,3]thiazin-4-one
skeleton. The presence of the hydrophobic substituents (Et,
Cl) in the benzenediol moiety increases their antiproliferative
potency. The evaluation in silico of the compounds showed
that they possess signiﬁcant drug-like characteristics, they are
metabolically stable and possess low or medium toxicity pro-
ﬁle. For the most active 6-tert-butyl-2-(5-chloro-2,4-dihydroxy
phenyl)-4H-thieno[3,2-d][1,3]thiazin-4-one (2c) low toxicity
was assumed and the compound can be further studied as a
potential anticancer agent. Very promising ADMET proper-
ties were predicted for compound 1d which displays a low
antiproliferative potency. Therefore, for this compound, it
would be desirable to try to indicate other directions of biolog-
ical activities than considered. Additionally, next studies
including design, synthesis, and evaluation of novel groups
of compounds with the modiﬁed 2,4-dihydroxyphenyl sub-
stituent as potential anticancer agents should be carried out.
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